Type 1 diabetes (T1D) is an autoimmune disease that occurs when a person’s pancreas stops producing insulin, the hormone that controls blood-sugar levels. T1D develops when the insulin-producing pancreatic beta cells are mistakenly destroyed by the body’s immune system. The cause of this attack is still being researched, however scientists believe the cause may have genetic and environmental components.
Sedentary lifestyle, unhealthy diet, lack of exercise and increasing prevalence of diabetes are key driver for Type 1 Diabetes (T1D) market. Insulin therapy is very much essential in the patients who have type 1 diabetes. Rising launch of the novel insulin formulations along with several adjunct therapies will positively impact the insulin acceptance. On the other hand, this chronic disorder poses a significant economic impact owing to the increasing cost of insulin coupled with other conditions such as cardiac disorders, kidney disease among others. While insulin therapy keeps people with T1D alive and can help keep blood-glucose levels within recommended range, it is not a cure, nor does it prevent the possibility of T1D’s serious effects. Although T1D is a serious and challenging disease, long-term management options continue to evolve, allowing those with T1D to have full and active lives. Asia Pacific region recorded the highest growth rate over the forecast period owing to the increasingly sedentary lifestyles, obese population, and improper food habits. North America accounted for more than 50% of the total market share over the forecast period.

The global Type 1 Diabetes (T1D) market was valued at 1960 million US$ in 2018 and will reach 2810 million US$ by the end of 2025, growing at a CAGR of 4.6% during 2019-2025.
This report focuses on Type 1 Diabetes (T1D) volume and value at global level, regional level and company level. From a global perspective, this report represents overall Type 1 Diabetes (T1D) market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Type 1 Diabetes (T1D) in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Type 1 Diabetes (T1D) manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Novo Nordisk
Sanofi
Eli Lilly
Merck
Boehringer Ingelheim
Samsung Bioepis
Biocon
Astellas
Janssen
Bristol-Myers Squibb
Lexicon
Sanofi

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Rapid Acting Insulin Analogs
Long Acting Insulin Analogs
Premix Insulin Analogs

Segment by Application
Children
Adults